Next Article in Journal
A Scoping Review of Modifiable Risk Factors in Pediatric Onset Multiple Sclerosis: Building for the Future
Next Article in Special Issue
Minimally Invasive Surgery in Pediatric Surgical Oncology
Previous Article in Journal / Special Issue
Pediatric Solid Tumors in Resource-Constrained Settings: A Review of Available Evidence on Management, Outcomes, and Barriers to Care
Review

Biological Drivers of Wilms Tumor Prognosis and Treatment

1
Vanderbilt University School of Medicine, Vanderbilt University, Nashville, TN 37232, USA
2
Department of Pediatrics, Division of Pediatric Hematology-Oncology, Vanderbilt University Medical Center Nashville, TN 37232, USA
3
Department of Pediatric Surgery, Vanderbilt University Medical Center Nashville, TN 37232, USA
*
Author to whom correspondence should be addressed.
Children 2018, 5(11), 145; https://doi.org/10.3390/children5110145
Received: 29 September 2018 / Revised: 16 October 2018 / Accepted: 18 October 2018 / Published: 26 October 2018
(This article belongs to the Special Issue Pediatric Surgical Oncology)
Prior to the 1950s, survival from Wilms tumor (WT) was less than 10%. Today, a child diagnosed with WT has a greater than 90% chance of survival. These gains in survival rates from WT are attributed largely to improvements in multimodal therapy: Enhanced surgical techniques leading to decreased operative mortality, optimization of more effective chemotherapy regimens (specifically, dactinomycin and vincristine), and inclusion of radiation therapy in treatment protocols. More recent improvements in survival, however, can be attributed to a growing understanding of the molecular landscape of Wilms tumor. Particularly, identification of biologic markers portending poor prognosis has facilitated risk stratification to tailor therapy that achieves the best possible outcome with the least possible toxicity. The aim of this review is to (1) outline the specific biologic markers that have been associated with prognosis in WT and (2) provide an overview of the current use of biologic and other factors to stratify risk and assign treatment accordingly. View Full-Text
Keywords: Wilms tumor; nephroblastoma; tumor biology; biomarkers; therapy Wilms tumor; nephroblastoma; tumor biology; biomarkers; therapy
MDPI and ACS Style

Phelps, H.M.; Kaviany, S.; Borinstein, S.C.; Lovvorn, H.N., III. Biological Drivers of Wilms Tumor Prognosis and Treatment. Children 2018, 5, 145. https://doi.org/10.3390/children5110145

AMA Style

Phelps HM, Kaviany S, Borinstein SC, Lovvorn HN III. Biological Drivers of Wilms Tumor Prognosis and Treatment. Children. 2018; 5(11):145. https://doi.org/10.3390/children5110145

Chicago/Turabian Style

Phelps, Hannah M., Saara Kaviany, Scott C. Borinstein, and Harold N. Lovvorn III. 2018. "Biological Drivers of Wilms Tumor Prognosis and Treatment" Children 5, no. 11: 145. https://doi.org/10.3390/children5110145

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop